EQS-News

Volta Medical Announces Late-Breaking TAILORED-AF Randomized Clinical Trial Results at Heart Rhythm 2024 in Boston, MA, USA - Seite 2

PO-484254 Saturday, May 18, 2024 Tailored Cardiac Ablation Procedure for Persistent Atrial Fibrillation Guided by Artificial Intelligence: The TAILORED-AF Randomized Clinical Trial Deisenhofer, I Late Breaking Clinical Trials Late Breaking Clinical Trials and Science - Innovation 9:30-9:40 Ballroom East West – BCEC
LB-469805

Volta’s AF-Xplorer identifies and annotates unique abnormalities (spatiotemporal dispersed electrograms) on 3D anatomical and electrical maps of the heart. This AI companion technology may help electrophysiologists to optimize catheter-ablation procedures for complex arrhythmias, including persistent AF.

Professor Isabel Deisenhofer will share findings from the TAILORED-AF clinical trial. The clinical trial is a transatlantic, multicenter, randomized, controlled study designed to determine if a tailored AI software-guided ablation strategy targeting areas of dispersion in combination with pulmonary vein isolation (PVI) is superior to a conventional anatomical ablation strategy targeting PVI alone for the treatment of persistent AF. TAILORED-AF was conducted in 26 sites and five countries.

Volta Medical is hosting a Rhythm Theater presentation, “The Future of AI Implementation in AF Ablation Procedures”. It will be moderated by Dr. Andrea Natale with a panel featuring Dr. Dhanunjaya “DJ” Lakkireddy (Kansas City Heart Rhythm Institute), Dr. Stavros Mountantonakis (Northwell Health, New York), Dr. Smit Vasaiwala (Loyola University Medical Center, Maywood), and Dr. Jean Paul Albenque (Clinique Pasteur, Toulouse).  This will be a comprehensive look at how intra-operative AI solutions can greatly enhance the physician’s assessment of complex AF, of which AF-Xplorer is one of the first examples in electrophysiology (EP).